Alphabet Replaces Verizon in Dow Jones Industrial Average 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
HEIDELBERG, Germany, Feb. 22, 2016 -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that its CMO, Jens-Peter Marschner, will present at the symposium titled "Emerging Approaches in Cancer Immunotherapy" in New York City on Monday, February 29 at 12:10-12:40 pm Eastern Standard Time. The symposium will be presented as part of the New York Academy of Sciences' Cancer and Signaling Discussion Group, which provides a forum for scientists from academia, industry, and government, as well as other stakeholders, to come together to explore cutting-edge topics in the field. A live webcast of Affimed's presentation will be available through the New York Academy of Sciences' website at www.nyas.org.
About Affimed N.V.
Affimed (Nasdaq:AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.
CONTACT: IR Contact:
Caroline Stewart, Head of IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: [email protected]
